Trials / Approved For Marketing
Approved For MarketingNCT03123965
Expanded Access to Glecaprevir/ Pibrentasvir
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- AbbVie · Industry
- Sex
- —
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to glecaprevir/ pibrentasvir prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | glecaprevir | Glecaprevir will be administered orally. |
| DRUG | pibrentasvir | Pibrentasvir will be administered orally. |
Timeline
- First posted
- 2017-04-21
- Last updated
- 2020-01-18
Locations
1 site across 1 country: Slovenia
Source: ClinicalTrials.gov record NCT03123965. Inclusion in this directory is not an endorsement.